US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inspire Corporate Bond ETF

23.84

0.0000

Post-market: 23.850.0142+0.06%16:10 EDT

Volume:35.06K

Turnover:835.52K

Market Cap:467.26M

PE:- -

High:23.90

Open:23.82

Low:23.80

Close:23.84

52wk High:24.85

52wk Low:23.51

Shares:19.60M

Float Shares:19.60M

Volume Ratio:0.60

T/O Rate:0.18%

Dividend:1.01

Dividend Rate:4.24%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug

MT Newswires Live

Veeco Announces $250 Million+ in Equipment Orders for Manufacturing Indium Phosphide Lasers

Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

Why High LNG Prices Could Spell Bad News for U.S. Exporters -- WSJ

Energy Crisis Gives a Crew of Farming Microbes a Shot at Redemption -- WSJ

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Hong Kong Regulators Uncover Major Insider Trading Scheme Involving Two Chinese Brokerages

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

SINOMAB BIO-B Receives NMPA Clearance for SM17 IBD Clinical Trial Application

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.84,"timestamp":1780084800000,"preClose":23.84,"halted":0,"volume":35056,"hourTrading":{"tag":"盘后","latestPrice":23.8542,"preClose":23.84,"latestTime":"16:10 EDT","volume":12,"amount":286.12,"timestamp":1780085405160,"change":0.0142,"changeRate":0.000596,"amplitude":0},"delay":0,"changeRate":0,"floatShares":19600000,"shares":19600000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"05-29 16:00:00 EDT","open":23.82,"high":23.895,"low":23.8,"amount":835515,"amplitude":0.003985,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.84,"sharesOutstanding":19800000,"nav":23.81,"aum":466715271.14,"dividendRate":0.042429,"bidAskSpread":0.002815,"preHourTrading":{"tag":"盘前","latestPrice":23.84,"preClose":23.84,"latestTime":"07:38 EDT","volume":1,"amount":23.84,"timestamp":1780054680107,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":23.8542,"preClose":23.84,"latestTime":"16:10 EDT","volume":12,"amount":286.12,"timestamp":1780085405160,"change":0.0142,"changeRate":0.000596,"amplitude":0},"volumeRatio":0.6022043251618127},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":19600000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6022043251618127,"shares":19600000,"dividePrice":1.0115,"high":23.895,"amplitude":0.003985,"preClose":23.84,"low":23.8,"week52Low":23.51,"pbRate":"--","week52High":24.85,"institutionHeld":0,"latestPrice":23.84,"eps":0,"divideRate":0.042429,"volume":35056,"delay":0,"ttmEps":0,"open":23.82,"prevYearClose":24.2,"prevWeekClose":23.706,"prevMonthClose":23.86,"prevQuarterClose":23.857,"fiveDayClose":23.81,"twentyDayClose":23.86,"sixtyDayClose":24.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-05-22","symbol":"IBD","amount":0.0776,"announcedDate":"2026-05-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-22","defaultRemindTime":1779456600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-05-22","currency":"USD","dateTimestamp":1779422400000,"payDate":"2026-05-27"},{"date":"2026-04-24","symbol":"IBD","amount":0.0788,"announcedDate":"2026-04-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-24","defaultRemindTime":1777037400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-29","payableDate":"2026-04-24","currency":"USD","dateTimestamp":1777003200000,"payDate":"2026-04-29"},{"date":"2026-03-27","symbol":"IBD","amount":0.0932,"announcedDate":"2026-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-27","defaultRemindTime":1774618200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-01","payableDate":"2026-03-27","currency":"USD","dateTimestamp":1774584000000,"payDate":"2026-04-01"},{"date":"2026-02-24","symbol":"IBD","amount":0.0779,"announcedDate":"2026-02-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-24","defaultRemindTime":1771943400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-02","payableDate":"2026-02-24","currency":"USD","dateTimestamp":1771909200000,"payDate":"2026-03-02"},{"date":"2026-01-27","symbol":"IBD","amount":0.0592,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635363712","title":"Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635363712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635363712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"--New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD--. --Company Continues to Advance Multiple Partnering Options for Nebokitug--. TEL AVIV, Israel, May 14, 2026  -- Chemomab Therapeutics Ltd. , , a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.-- On May 30, 2026, Chemomab will present data from three abstracts at EASL. -- In one EASL 2026 study1, Olink-generated analyses of circulating. proteins in patient samples from the SPRING trial were used to. generate an AI/machine learning model to identify patients who. showed a combined improvement in all three key fibrosis-related. measures: ELF sc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DM0.SI","BK4007","BK4116","IBD","CMMB","LENZ","R","BK4022","BK4023","BK4539","BK6053","PSC","CD","BK4139","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477456","title":"Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477456","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634477456?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:20","pubTimestamp":1778480432,"startTime":"0","endTime":"0","summary":"Mabwell  Bioscience's  clinical trial application for 9MW521, a novel injection targeting Inflammatory Bowel Disease , was formally cleared by the US Food and Drug Administration, according to a May 8 Hong Kong bourse filing.Shares of the pharmaceutical firm were up nearly 4% in Monday afternoon trading.The drug will be tested as a treatment for inflammatory bowel disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK0239","LABU","02493","IBD","688062","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925059","title":"Veeco Announces $250 Million+ in Equipment Orders for Manufacturing Indium Phosphide Lasers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925059","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925059?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:03","pubTimestamp":1778011380,"startTime":"0","endTime":"0","summary":"High-volume orders from multiple customers for its Spector, Lumina and Wet Processing Systems to drive strong growth. PLAINVIEW, N.Y., May  05, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ:","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288217/0/en/Veeco-Announces-250-Million-in-Equipment-Orders-for-Manufacturing-Indium-Phosphide-Lasers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4147","IE0031619046.USD","IE00B19Z4B17.USD","VECO","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948138","title":"Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948138?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment of the Phase 3 APOLLO study of bitopertin in. erythropoietic protoporphyria ; topline data expected in Q4 2026. -- Updated data from Phase 2 study of DISC-0974 in patients with anemia of. myelofibrosis  to be shared at the American Society of Clinical. -- Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera . and Phase 1b study of DISC-3405 in sickle cell disease , with data. cash, cash equivalents, and marketable securities, providing runway into. adults and adolescents with EPP, with topline data expected Q4 2026;anemia of myelofibrosis  to be shared in an oral presentation at ASCO. -- Progressing Phase 2 study in patients with inflammatory bowel disease","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","EPP","SCD","LU0053671581.USD","IRON","BK4139","BK4582"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632305519","title":"Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2632305519","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632305519?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:00","pubTimestamp":1777892400,"startTime":"0","endTime":"0","summary":"Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286554/0/en/Seres-Therapeutics-Presents-Preclinical-Data-at-Digestive-Disease-Week-DDW-2026-Supporting-SER-603-a-Next-Generation-Cultivated-Live-Biotherapeutic-Candidate-for-Inflammatory-Bowel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","MCRB","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","RA","LU0072461881.USD","ATS","BK4161","LU0320765646.SGD","LU0006061336.USD","LU0162691827.USD","EASI","LU1162221912.USD","BK4588","BK4006","KYMR","BK4201","BP","BK4139","PN","BK4132","BK4585","LU1829250122.USD","IBD","BPH","SID","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU2111349929.HKD","IBD","LU0882574139.USD","LU2089284900.SGD","LU0912757837.SGD","LU2133065610.SGD","LU2357305700.SGD","LU0314104364.USD","LU2089283258.USD","BK4127","LU0971096721.USD","LU0158827948.USD","ITP","LU0320765646.SGD","LU0106831901.USD","BK4132","LU0234570918.USD","BK4077","LU1162221912.USD","BK4588","LU1989772923.USD","LU1791710400.SGD","IE00BKVL7J92.USD","BK4585","LU1244550494.USD","LU2347655156.SGD","BK4199","LU2271345857.HKD","LU2023251221.USD","LU1244550221.USD","LU1732800096.USD","LU0225283273.USD","LU0006306889.USD","BK4534","LU1244550577.SGD","BK4581","LU0158827781.USD","LU0557290698.USD","AD","LU0106261372.USD","LU1732799900.SGD","LU2028103732.USD","BK4516","LU1074936037.SGD","LU1720051017.SGD","LU0795875086.SGD","SLE","LU0528227936.USD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174260","title":"Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174260","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174260?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:00","pubTimestamp":1776682800,"startTime":"0","endTime":"0","summary":"Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276845/0/en/Seres-Therapeutics-Showcases-SER-155-Data-and-Live-Biotherapeutic-Insights-at-ESCMID-Global-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMR","BK4139","BK4006","BK4585","MCRB","SER","IBD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628559249","title":"Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628559249","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628559249?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:15","pubTimestamp":1776370500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275826/0/en/Spyre-Therapeutics-Inc-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-for-Gross-Proceeds-of-463-5-Million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IBD","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627714114","title":"Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2627714114","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627714114?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:38","pubTimestamp":1776220680,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274098/0/en/Spyre-Therapeutics-Announces-Pricing-of-Upsized-403-0-Million-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","IBD","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627465756","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2627465756","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627465756?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:46","pubTimestamp":1776113160,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/13/3272916/0/en/Spyre-Therapeutics-Announces-Proposed-Public-Offering-of-its-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","HK0000165453.HKD","LU0225284248.USD","ADA.AU","IND","LU0456855351.SGD","BK7095","BK4218","BK7016","LU0289739699.SGD","BK4585","01530","BK4592","BK4568","BK4581","BK4534","BK1583","IND.AU","SG9999001176.USD","BK4007","LU0321505439.SGD","BK4588","CLDT","BK1161","SAA","SG9999002232.USD","BK1593","LU0306806265.USD","IE0002270589.USD","LU0985481810.HKD","PFE","BRVO","IE00B19Z3B42.SGD","BK4077","IE00BLSP4452.SGD","ITP","LU0321505868.SGD","LU1066053197.SGD","LU1894683264.USD","SG9999003800.SGD","LU1894683348.USD","SG9999013999.USD","BK4181","IE000M9KFDE8.USD","BK4599","LU1883839398.USD","SG9999011175.SGD","IE00B19Z3581.USD","IBD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622863413","title":"Why High LNG Prices Could Spell Bad News for U.S. Exporters -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2622863413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622863413?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:31","pubTimestamp":1774531860,"startTime":"0","endTime":"0","summary":"\"Natural gas, delivered at a fraction of the cost in a fraction of the time,\" says Billy Bob Thornton in a new commercial for liquefied-natural-gas exporter Venture Global.Thornton, whose voice accompanies images of an export facility being built, is associated with the oil patch these days, thanks to his role in the TV series \"Landman.\" But it's a jarring moment to hear LNG described as low-cost. Prices have jumped since the Iran war knocked Qatar, the second-biggest producer, out of the market.U.S. LNG producers stand to gain market share. Shares in Venture Global have soared since the war started. It sells a greater share of its gas in the spot market than other exporters, giving it more exposure to rising prices .But the current high prices are already boosting the appeal of alternatives, from renewables to coal.\" It's a scary thing, it's not good for our industry,\" said Michael Smith, chief executive of Freeport LNG, an exporter, at an energy conference in Houston this week.The LN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","IBD","VDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618374731","title":"Energy Crisis Gives a Crew of Farming Microbes a Shot at Redemption -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2618374731","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618374731?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:56","pubTimestamp":1773323760,"startTime":"0","endTime":"0","summary":"An energy crisis spells opportunity. Chris Abbott is hoping this one doesn't pan out like the last one.Abbott is chief executive of Pivot Bio, a company that sells plant-nourishing microbes, and war in Iran has created an opening.On the U.S. Gulf Coast, the price of urea, the most widely used fertilizer, has risen 35% since the U.S. and Israel attacked Iran. It is made from natural gas, and roughly 30% of global exports come from the Middle East, largely through the off-limits Strait of Hormuz. The price shock, ahead of spring planting, threatens farmers already dealing with low crop prices.But Abbott's microscopic farmhands, grown in fermenters, don't get more expensive when fossil fuels do. Now, demand for them is ramping up. But the last time this story played out, after Russia invaded Ukraine, it ended badly.\"We were selling out,\" Abbott said. \"That was probably the worst thing that ever happened to us.\". In 2022, Pivot Bio's microbes were used on 3 million acres of corn, more than","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","SG9999002224.SGD","BK4082","IE00B2B36J28.USD","BK4568","LU1691799644.USD","LU2237957902.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","ABT","LU0058720904.USD","BK4570","BK4585","BK4588","IE00B4R5TH58.HKD","LU1989763427.SGD","SGXZ23171101.USD","BK4566","LU0882574055.USD","LU2211815571.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","IBD","LU1023059063.AUD","SG9999004303.SGD","LU1061106388.HKD","LU0114720955.EUR","XOP","BK4504","LU0289739699.SGD","DUG","BK4592","LU2324357040.USD","LU0234572021.USD","LU1721429402.USD","LU0170899867.USD","BK4533","LU1989763690.USD","LU1914381329.SGD","LU2112291526.USD","LU2133065610.SGD","IE00BJJMRZ35.SGD","LU1721429741.USD","LU0868494617.USD","SGXZ41872573.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618136124","title":"Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618136124","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618136124?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313200,"startTime":"0","endTime":"0","summary":"Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track fo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254451/0/en/Seres-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","MCRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183642681","title":"Hong Kong Regulators Uncover Major Insider Trading Scheme Involving Two Chinese Brokerages","url":"https://stock-news.laohu8.com/highlight/detail?id=1183642681","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183642681?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:48","pubTimestamp":1773312495,"startTime":"0","endTime":"0","summary":"Hong Kong's financial sector is facing a major upheaval following a significant regulatory crackdown. According to informed sources cited by Bloomberg, Hong Kong authorities conducted surprise raids...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1155","03317","HK0000914660.USD","LU0738911758.USD","BK4526","LU1066051498.USD","LU1066051811.HKD","LU0426417589.USD","LU0545562505.USD","LU0426412945.USD","LU0265550359.USD","SG9999011175.SGD","LU0690374615.EUR","BK4505","LU2381873111.SGD","IE000M9KFDE8.USD","BK4539","LU1043141123.HKD","LU2404859741.USD","PM","GB00B4LPDJ14.GBP","GB00B4QBRK32.GBP","LU0949170772.SGD","LU0265550946.USD","BK4585","LU1066053197.SGD","LU1121112475.USD","LU0661504455.SGD","DIDI","LU0314106906.USD","LU1066051225.USD","LU0994945656.USD","BK4561","LU1116320737.USD","LU1043141396.HKD","IBD","LU1116320901.HKD","BK4022","LU2404859667.USD","BK4535","BK4588","LU1228905540.USD","LU1506573853.SGD","LU1914381329.SGD","BK4075","BK4531","SG9999001440.SGD","SG9999003800.SGD","BK4566","LU1228905037.USD","HK0000914686.HKD","LU0690374961.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616361978","title":"Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616361978","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616361978?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:05","pubTimestamp":1772485500,"startTime":"0","endTime":"0","summary":"Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247853/0/en/Seres-Therapeutics-Announces-Appointment-of-Richard-N-Kender-as-Executive-Chair-and-Interim-CEO-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4139","MCRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614042239","title":"Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614042239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614042239?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:30","pubTimestamp":1772112600,"startTime":"0","endTime":"0","summary":"-- Pursuing a traditional approval path for bitopertin in erythropoietic. protoporphyria ; Phase 3 APOLLO study is expected to complete. enrollment in March 2026 with topline data expected in Q4 2026. -- Initial data from Phase 2 study of DISC-0974 in patients with anemia of. myelofibrosis  presented at the American Society of Hematology . conference demonstrating meaningful overall anemia responses across all. patient subgroups, regardless of baseline transfusion status or. -- Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera . and initiated a Phase 1b study of DISC-3405 in sickle cell disease . in Q4 2025, with data from both studies expected in 2H 2026. cash, cash equivalents, and marketable securities, providing runway into. Administration  in February 2026 related to sufficiency of evidence. adolescents with EPP, with topline data expected Q4 2026. anemia of myelofibrosis  presented at ASH Annual Meeting i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4588","EPP","BK4139","LU0053671581.USD","IE00BFMHRM44.USD","BK4582","LU2463526074.USD","LU0029874061.USD","BK4530","BK4109","CRL","SCD","BK4585","LU0757428866.USD","IBD","LU1815336091.USD","LU0390134368.USD","BK4121","LU0128526141.USD","ASH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614304489","title":"Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304489","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614304489?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107200,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245428/0/en/Kymera-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4132","EASI","LU0320765646.SGD","LU0162691827.USD","BK4585","BPH","ACR","PN","LU0072461881.USD","AD","LU1162221912.USD","BK4139","BK4110","BK4096","LU1829250122.USD","BK4201","BP","RA","KYMR","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105876866","title":"SINOMAB BIO-B Receives NMPA Clearance for SM17 IBD Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1105876866","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105876866?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:10","pubTimestamp":1771942248,"startTime":"0","endTime":"0","summary":"SINOMAB BIO-B (03681) announced that on February 24, 2026, the Investigational New Drug (IND) application for its first-in-class (FIC) therapeutic product SM17, intended for the treatment of patients...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03681","IND","IBD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}